制御性T細胞（Treg）- 市場規模、標的集団、競合情勢、市場予測（2034年）

主なハイライト

• Tregに基づく治療とTregを標的とする治療は、自己免疫疾患、腫瘍学、神経変性疾患に有意義な効果をもたらします。
• 主要7市場におけるTregの市場規模は、予測期間に大幅なCAGRで増加する見込みです。主要7市場中では米国が最大の市場規模、すなわち2034年までに市場全体の約76%を占めると推定されます。
• 2023年、主要7市場におけるTregの選択された適応症の総患者数は4,556万4,626人でした。これらの患者数は2034年までに増加すると予測されます。すべての適応症の中で、アトピー性皮膚炎の患者数がもっとも多いです。
• 広範な疾患を対象としたTreg治療における有望な進歩にもかかわらず、現在承認された治療法はなく、重大なアンメットニーズを浮き彫りにしています。このギャップは、この分野における先行者利益の可能性を明示するものであり、重要な治療領域に対処する機会があります。
• Treg治療のパイプラインは非常に有望であり、中期/早期開発段階にある数多くの重要なアセットを有しています。Rapa Therapeutics（RAPA-501）、TRACT TherapeuticsとTaiwan Bio Therapeutics（TRK-001）、Quell Therapeutics（QEL-001）、Nektar（rezpegaldesleukin）Georgiamune（GIM-531）、Sangamo Therapeutics（TX200）、Abat Therapeutics（ABA-101）、Novabio Therapeutics（NP001細胞注射）、Cellenkos（CK0801）、CellenkosとIncyte（CK0804）、ILTOO Pharma（ILT-101）、Coya TherapeuticsとDr.Reddy's Laboratories（Coya 302）などの主要企業が、幅広い疾患をターゲットとした効果的なTreg治療法を開発しています。
• パイプラインには、Treg増強生物製剤、Treg由来のエクソソーム技術、自家および同種Treg細胞療法があり、新たに登場した同種の「off-the-shelf」製品は、スケーラビリティの向上とコスト削減の可能性を提供しています。
• Tregパイプラインの主な適応症には、生体腎移植における同種移植片拒絶反応予防に用いるTRK-001や、肝移植拒絶反応予防に用いるQEL-001などの主なアセットによる移植（肝臓、腎臓、造血幹細胞移植）における拒絶反応の予防があり、一方、Tacrolimusを含むOrca-TやRGI-2001は、alloHSCTを受ける進行性の血液悪性腫瘍における移植片対宿主病（GvHD）の予防を対象としています。筋萎縮性側索硬化症もパイプラインの重要な焦点であり、RAPA-501、COYA302、ILT-101などの注目すべき治療薬が開発中です。
• これらの初期段階から後期段階の治療薬に加えて、この部門にはQuell TherapeuticsのQEL-004、QEL-002、QEL-003、Abata TherapeuticsのABA 201、Parvus TherapeuticsのPVT401、その他の数種類を含む、幅広い自己免疫疾患を標的とする前臨床候補の多様なパイプラインもあります。
• 今後、Treg治療は強力なパイプライン、精密医療の進歩、自己免疫疾患や炎症性疾患の有病率の増加による大きな成長が見込まれます。

Treg市場の見通し

過去10年間でT細胞療法は大きな変革を遂げました。Treg抵抗性とTreg機能不全を複合的なアプローチで標的とするという考えはまだ比較的新しく、発展途上です。FOXP3転写因子を発現するCD4+ T細胞の特殊なサブセットとして発見されたTregは、過剰な免疫活性化を抑制し、自己免疫反応を予防するために不可欠です。長年にわたる免疫学の進歩により、自己免疫疾患、慢性炎症性疾患、移植拒絶反応の治療におけるTregの可能性が示されてきました。

• 主要7市場のうち、米国が2034年に約76%と最大の市場シェアを占めます。
• 欧州4ヶ国・英国では、2034年までにドイツが最大の市場規模を持ち、スペインは最下位になると推定されています。
• すべての適応症の中で、T1DMが2034年までに主要7市場の大半の市場シェアに寄与します。
• 2034年までに、米国ではすべての治療薬の中でPTG-007/PTG007-DM1の収益がもっとも高く、CK0801の収益がもっとも低くなると予測されます。

当レポートでは、制御性T細胞（Treg）の主要7市場（米国、ドイツ、スペイン、イタリア、フランス、英国、日本）について調査分析し、各地域の市場規模、現在の治療法、アンメットニーズ、新薬などの情報を提供しています。

目次

第1章 重要考察

第2章 レポートのイントロダクション

第3章 エグゼクティブサマリー

第4章 重要な出来事

第5章 疫学と市場予測の調査手法

第6章 主要7市場のTreg市場の概要：適応症別

• 市場シェアの分布：適応症別（2028年）
• 市場シェアの分布：適応症別（2034年）

第7章 主要7市場のTreg市場の概要

• 市場シェアの分布：治療法別（2028年）
• 市場シェアの分布：治療法別（2034年）

第8章 疾患の背景と概要

• イントロダクション
• Tregとその分類
• さまざまな適応症の治療におけるTregの可能性
• Tregに関連するバイオマーカー
• Tregの臨床応用

第9章 疫学と標的集団

• 主な調査結果
• 前提条件と根拠：主要7市場
• 主要7市場の疫学シナリオ

第10章 新薬

• 主な競合相手
• Orca-T：Orca Bio
• RAPA-501：Rapa Therapeutics
• TRK-001：TRACT Therapeutics、Taiwan Bio Therapeutics
• ILT-101：ILTOO Pharma
• Rezpegaldesleukin（REZPEG、NKTR-358、LY3471851）：Nektar
• PTG-007：PolTREG
• RGI-2001：REGiMMUNE
• QEL-001：Quell Therapeutics
• GIM-531：Georgiamune
• TX200（TX200-TR101）：Sangamo Therapeutics
• EGL-001：Egle Therapeutics
• Tivumecirnon（FLX475）：RAPT Therapeutics
• TRX103：Tr1X
• IPG7236：Nanjing Immunophage Biotech
• CK0804：Cellenkos、Incyte
• ABA-101：Abata Therapeutics
• NP001 Cell Injection：Novabio Therapeutics
• CK0801：Cellenkos
• SBT-77-7101：Sonoma Biotherapeutics
• CK0803：Cellenkos
• SBT-11-5301：Sonoma Biotherapeutics
• COYA 302：Coya Therapeutics、Dr. Reddy's Laboratories
• CUG252：Cugene/AbbVie
• DT2216：Dialectic Therapeutics

第11章 Treg：主要7市場の分析

• 主な調査結果
• 市場見通し
• コンジョイント分析
• 主な市場予測の前提条件
• 主要7市場のTregの市場規模
• 米国の市場規模
  • 米国のTregの市場規模：適応症別
  • 米国の市場規模：治療法別
• 欧州4ヶ国・英国の市場規模
  • 欧州4ヶ国・英国のTregの市場規模：適応症別
  • 欧州4ヶ国・英国の市場規模：治療法別
• 日本の市場規模
  • 日本のTregの市場規模：適応症別
  • 日本の市場規模：治療法別

第12章 アンメットニーズ

第13章 SWOT分析

第14章 KOLの見解

第15章 市場参入と償還

• 米国
• 欧州4ヶ国・英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • 英国
• 日本

第16章 付録

第17章 DelveInsightのサービス内容

第18章 免責事項

第19章 DelveInsightについて

List of Tables

• Table 1: Summary of Tregs Market and Epidemiology (2020-2034)
• Table 2: Phenotype and Characteristics of Tregs Under Various Classification
• Table 3: List of Sources Used for Epidemiology Evaluation for Shortlisted Indication
• Table 4: Total Cases of Selected Indications in the 7MM in thousand (2020-2034)
• Table 5: Indication-wise Eligible Cases in the 7MM in thousand (2020-2034)
• Table 6: Indication-wise Treated Cases in the 7MM in thousand (2020-2034)
• Table 7: Comparison of Emerging Drugs Under Development
• Table 8: Orca-T, Clinical Trial Description, 2024
• Table 9: RAPA-501, Clinical Trial Description, 2024
• Table 10: TRK-001, Clinical Trial Description, 2024
• Table 11: ILT-101, Clinical Trial Description, 2024
• Table 12: Rezpegaldesleukin (REZPEG; NKTR-358; LY3471851), Clinical Trial Description, 2024
• Table 13: QEL-001, Clinical Trial Description, 2024
• Table 14: GIM-531, Clinical Trial Description, 2024
• Table 15: TX200, Clinical Trial Description, 2024
• Table 16: EGL-001, Clinical Trial Description, 2024
• Table 17: Tivumecirnon (FLX475), Clinical Trial Description, 2024
• Table 18: IPG7236, Clinical Trial Description, 2024
• Table 19: CK0804, Clinical Trial Description, 2024
• Table 20: ABA-101, Clinical Trial Description, 2024
• Table 21: NP001 Cell Injection, Clinical Trial Description, 2024
• Table 22: CK0801, Clinical Trial Description, 2024
• Table 23: SBT-77-7101, Clinical Trial Description, 2024
• Table 24: CK0803, Clinical Trial Description, 2024
• Table 25: SBT-11-5301, Clinical Trial Description, 2024
• Table 26: CUG252, Clinical Trial Description, 2024
• Table 27: DT2216, Clinical Trial Description, 2024
• Table 28: Key Market Forecast Assumption of Tregs in the United States
• Table 29: Key Market Forecast Assumption of Tregs in EU4 and the UK
• Table 30: Key Market Forecast Assumption of Tregs in Japan
• Table 31: Market size of Tregs by Country in the 7MM, USD million (2020-2034)
• Table 32: Market size of Tregs by Indications in the US, USD million (2020-2034)
• Table 33: Market Size by Therapies in the US, USD million (2020-2034)
• Table 34: Market size of Tregs by Indications in EU4 and the UK, USD million (2020-2034)
• Table 35: Market Size by Therapies in EU4 and the UK, USD million (2020-2034)
• Table 36: Market size of Tregs by Indications in Japan, USD million (2020-2034)
• Table 37: Market Size by Therapies in Japan, USD million (2020-2034)

List of Figures

• Figure 1: T-cell Differentiation and Subsets
• Figure 2: Mechanisms Underlying Treg-mediated Immunosuppression
• Figure 3: Treg Supplementation Therapies for Autoimmunity and Lupus Nephritis
• Figure 4: The Role of Tregs in Psoriasis Pathogenesis
• Figure 5: The Role of Treg in the Pathogenesis of Early Systemic Sclerosis
• Figure 6: Mechanism of Action of Treg cells and Their Alteration in Multiple Sclerosis
• Figure 7: Types of Gene-modified Antigen-specific Human Tregs
• Figure 8: Total Cases of Selected Indications in the 7MM (2020-2034)
• Figure 9: Indication-wise Eligible Cases in the 7MM (2020-2034)
• Figure 10: Indication-wise Treated Cases in the 7MM (2020-2034)
• Figure 11: Market size of Tregs in the 7MM, USD million (2020-2034)
• Figure 12: Market size of Tregs by Indications in the US, USD million (2020-2034)
• Figure 13: Market Size by Therapies in the US, USD million (2020-2034)
• Figure 14: Market size of Tregs by Indications in EU4 and the UK, USD million (2020-2034)
• Figure 15: Market Size by Therapies in EU4 and the UK, USD million (2020-2034)
• Figure 16: Market size of Tregs by Indications in Japan, USD million (2020-2034)
• Figure 17: Market Size by Therapies in Japan, USD million (2020-2034)
• Figure 18: Health Technology Assessment
• Figure 19: Reimbursement Process in Germany
• Figure 20: Reimbursement Process in France
• Figure 21: Reimbursement Process in Italy
• Figure 22: Reimbursement Process in Spain
• Figure 23: Reimbursement Process in the United Kingdom
• Figure 24: Reimbursement Process in Japan

Key Highlights:

• Treg-based therapies and targeting Tregs have a meaningful effect on autoimmune disease, oncology, and neurodegenerative disorders.
• The market size of Tregs in the 7MM is expected to increase with a significant CAGR during the forecast period. Among the 7MM, the United States is estimated to have the largest market size, i.e., approximately 76% of the overall market by 2034.
• In 2023, the total cases of selected indications for Tregs were 45,564,626 cases in the 7MM. These cases are expected to increase by 2034. Among all the indication, atopic dermatitis accounted for highest number of cases.
• Despite the promising advancements in Treg therapies targeting a wide range of diseases, there are currently no approved treatments, highlighting a significant unmet need. This gap underscores the potential for first-mover advantage in the field, with opportunities to address critical therapeutic areas.
• The Treg therapy pipeline is highly promising, featuring numerous key assets in mid- and early-stage development. Key players, such as Rapa Therapeutics (RAPA-501), TRACT Therapeutics and Taiwan Bio Therapeutics (TRK-001), Quell Therapeutics (QEL-001), Nektar (rezpegaldesleukin) Georgiamune (GIM-531), Sangamo Therapeutics (TX200), Abata Therapeutics (ABA-101), Novabio Therapeutics (NP001 cell injection), Cellenkos (CK0801), Cellenkos and Incyte (CK0804), ILTOO Pharma (ILT-101), Coya Therapeutics and Dr. Reddy's Laboratories (Coya 302), among others are developing effective Treg therapies targeting a wide range of diseases.
• The pipeline features a diverse range of Treg-augmenting biologics, Treg-derived exosome technologies, and both autologous and allogeneic Treg cell therapies, with emerging allogeneic "off-the-shelf" products offering the potential to improve scalability and reduce costs.
• Among the leading indication in the Treg pipeline includes the prevention of rejection in transplant (Liver, Kidney and HSCT) with key assets such as TRK-001 for preventing allograft rejection in living donor kidney transplants and QEL-001 for liver transplant rejection prevention, while Orca-T with Tacrolimus and RGI-2001 targets the prevention of Graft versus Host Disease (GvHD) in advanced hematologic malignancies undergoing alloHSCT. Amyotrophic lateral sclerosis is another key focus in the pipeline, with notable therapies in development including RAPA-501, COYA 302, and ILT-101.
• In addition to these early-to-late-stage therapies, the field also features a diverse pipeline of preclinical candidates targeting a wide range of autoimmune diseases, including Quell Therapeutics's QEL-004, QEL-002, QEL-003, Abata Therapeutics's ABA 201, Parvus Therapeutics' PVT401, and several others.
• Looking ahead, Treg therapies are poised for significant growth, driven by a robust pipeline, precision medicine advancements, and rising autoimmune and inflammatory disease prevalence.

DelveInsight's "Regulatory T cells (Tregs) - Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report delivers an in-depth understanding of Tregs, historical and forecasted epidemiology as well as the Tregs market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The Tregs market report provides current treatment practices, emerging drugs, Tregs market share of individual therapies, and current and forecasted Tregs market size from 2020 to 2034, segmented by seven major markets. The report also covers current Tregs treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Geography Covered:

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2020-2034

Tregs Understanding and Treatment Algorithm

Tregs Overview

Over the last decade, T-cell therapy has taken a huge revolution. T cells are classified broadly into proinflammatory and anti-inflammatory populations that form three main groups, proinflammatory CD8 T, CD4 T Helper (Th) cells, and Regulatory T cells (Tregs). Tregs suppress inflammatory responses, promote immunological tolerance, and control immune responses to prevent autoimmunity. Treg-mediated immunosuppression involves several immune-suppressive mechanisms, including CTLA4-mediated APC suppression, IL-2 consumption, and immunosuppressive cytokines and metabolite production. Furthermore, the Treg-mediated inhibitory pathways impeding various immune cells have been classified as direct pathways, where Tregs induce a direct response on the immune cell, and indirect pathways, under which another cell or molecule is influenced, which in turn inhibit the immune cells.

Tregs development is more prominently rooted in immunology due to their role in maintaining immune balance or homeostasis. While Tregs are indeed a cornerstone of immunological research, their relevance to cancer is also seen, particularly in the Tumor Microenvironment (TME).

Tregs Epidemiology

Tregs epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by the Total Cases of Selected Indication for Tregs, Indication-wise Eligible Cases, and Indication-wise Treated Cases, in the 7MM, covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2020 to 2034.

• In 2023, the total cases of selected indications for Tregs were approximately 45,564,626 cases in the 7MM, which is anticipated to increase by 2034.
• Among all the indications, Atopic Dermatitis accounted for highest number of cases, while Aplastic Anemia occupied the bottom of the ladder.
• In the 7MM, Atopic Dermatitis accounted for highest number of indication-wise eligible cases, i.e., nearly 39,046,011 cases, in 2023.

Tregs Drug Chapters

Emerging Drugs

Orca-T: Orca Bio

Orca-T is an investigational allogeneic T-cell immunotherapy being evaluated in clinical trials for the treatment of multiple hematologic malignancies.

Orca-T is currently being evaluated in a pivotal Phase III clinical trial that has completed enrollment at leading transplant centers across the US. It is designed to deliver improved outcomes for patients while overcoming the limitations of standard allogeneic HSCT. The company is expecting topline results of the Orca-T pivotal Phase III clinical trial vs. a conventional allogeneic stem cell transplant in the first half of 2025.

RAPA-501: Rapa Therapeutics

RAPA-501 is a cell treatment that is thought to protect motor neurons from inflammation. RAPA-501 aims to increase the levels of Tregs in people with MND. The Phase I study successfully showed RAPA-501 to be safe in a small cohort of nine people. The open-label study offered most participants two doses over 42 days. The study also showed an increase in T-reg cell protective markers.

Currently, Rapa Therapeutics is conducting a Phase II/III clinical trial of RAPA-501 in patients with ALS, where the treatment has demonstrated safety (with no product-related adverse events), biological activity (exhibiting diverse anti-inflammatory effects), and early indications of potentially slowing the decline in pulmonary function. Rapa's clinical trial efforts using RAPA-501 have been partially supported by an award from the ALS Association.

Tregs Market Outlook

Over the last decade, T-cell therapy has taken a huge revolution. The idea of targeting Tregs resistance and Tregs dysfunction in a combined approach is still relatively new and in its infancy. Discovered as a specialized subset of CD4+ T cells expressing the FOXP3 transcription factor, Tregs are essential for suppressing excessive immune activation and preventing autoimmune reactions. Over the years, advancements in immunology have underscored the potential of Tregs in treating autoimmune disorders, chronic inflammatory diseases, and transplant rejection, as well as their modulation in cancer therapy.

The therapeutic potential of Tregs is expanding rapidly with next-generation approaches addressing earlier challenges. Polyclonal Tregs showed promise but faced issues like stability and scalability. Advances such as antigen-specific and CAR-Tregs now enable precise targeting of disease pathways with reduced side effects, reshaping the treatment landscape.

The market for Treg therapies remains wide open, as no treatments have been approved yet, signaling a substantial unmet need. The dynamics of Treg therapy market is anticipated to change as companies across the globe are thoroughly working toward the development of new Treg therapies options to treat a wide array of indications such as Systemic lupus erythematosus (SLE), lupus nephritis, Atopic dermatitis, Rheumatoid arthritis, Psoriasis, Progressive Multiple Sclerosis, Inflammatory Bowel Disease, Ulcerative Colitis, Crohn's Disease, Bone Marrow Failure Syndrome (BMF), Kidney Transplant, Myelofibrosis, Liver Transplant, Aplastic Anemia, Amyotropic Lateral Sclerosis (ALS), Hematopoietic stem-cell transplantation (HSCT), HNSCC, Triple negative breast cancer (TNBC), Type 1 diabetes, and others.

The therapeutic landscape is enriched by the growing number of clinical trials evaluating Treg therapies across other multiple indications. For instance, CK0801 (Cellenkos), a cord blood-derived Treg product, is being evaluated in Phase I for aplastic anemia. In type 1 diabetes, SBT-11-5301 is being evaluated early-stage trial, underscoring the broad potential of Treg therapies across a spectrum of diseases. Emerging candidates in the pipeline such as EGL-001 (Egle Therapeutics), DT2216 (Dialectic Therapeutics), IPG7236 (Nanjing Immunophage Biotech), Tivumecirnon (RAPT Therapeutics), GIM-531 (Georgiamune), CK0804 (Cellenkos), and others demonstrate the growing interest in leveraging Tregs for cancer therapy. Several candidates, such as TRK-001 (Phase II), Orca-T (Phase III), TX200 (Phase I/II), TRX103 (Phase I), RGI-2001 (Phase IIb), and others are under clinical evaluation to prevent graft-versus-host disease (GvHD). Several other companies are also evaluating their assets, actively contributing to this growing area of research.

• Among the 7MM, the US held the largest market share at approximately 76 % in the 7MM in 2034.
• Within the EU4 and the UK, Germany is estimated to have the largest market size, while Spain at the bottom, by 2034.
• Among all the indications T1DM will be the major market share contributor in 2034 in the 7MM.
• By 2034, among all the therapies, the highest revenue is expected to be generated by PTG-007/PTG007-DM1, while the lowest revenue is expected to be generated by CK0801 in the US.

Key Updates

• In October 2024, Nektar announced to publishing of the results from Phase Ib studies of rezpegaldesleukin in atopic dermatitis and psoriasis in nature communications.
• In October 2024, Egle Therapeutics presented preclinical efficacy data for EGL-001, a CTLA-4/CD25 antagonist fusion protein at the Society for Immunotherapy of Cancer Meeting.
• In October 2024, REGiMMUNE and Kiji Therapeutics announced an intention to merge companies, which will create a pan-global Treg specialist to use multiple modalities to target Tregs for several indications.
• In September 2024, Sonoma Biotherapeutics announced that it had received a USD 45 million milestone payment from Regeneron Pharmaceuticals under the terms of its active collaboration to discover, develop, and commercialize engineered Tregs therapies for autoimmune diseases.
• In August 2024, the FDA cleared the IND application for TRX103 to treat patients with refractory Crohn's disease.
• In August 2024, Abata Therapeutics announced the US FDA granted Fast Tract Designation (FTD) for ABA-101 for the treatment of patients with progressive multiple sclerosis.
• In March 2024, Sonoma Biotherapeutics and Regeneron Pharmaceuticals announced a collaboration for the discovery, development, and commercialization of novel Tregs therapies for autoimmune diseases.

Tregs Drugs Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during 2020-2034. The landscape of Tregs has experienced a profound transformation with the uptake of novel drugs. These innovative therapies are redefining standards of care. Furthermore, the increased uptake of these transformative drugs is a testament to the unwavering dedication of physicians, oncology professionals, and the entire healthcare community in their tireless pursuit of advancing cancer care. This momentous shift in treatment paradigms is a testament to the power of research, collaboration, and human resilience.

Tregs Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, Phase II/III, Phase II, and Phase I/II. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers detailed information on collaborations, acquisitions and mergers, licensing, and patent details for Tregs emerging therapies.

KOL- Views

To keep up with current market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Some of the leaders like MD, PhD, Research Project Manager, Director, and others. Their opinion helps to understand and validate current and emerging therapies and treatment patterns or Tregs market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Delveinsight's analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as the University of Michigan Kellogg Eye Center, Cedars-Sinai Medical Center, Laboratory of Endocrinology and Receptor Biology at NIDDK, University of Amsterdam, Cedars-Sinai Medical Center, Temple University School of Podiatric Medicine, Basedowian Ophthalmopathy Center, etc., were contacted. Their opinion helps understand and validate Tregs epidemiology and market trends.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT and conjoint analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

The analyst analyzes multiple emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry.

In efficacy, the trial's primary and secondary outcome measures are evaluated.

Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials.

Market Access and Reimbursement

Because newly authorized drugs are often expensive, some patients escape receiving proper treatment or use off-label, less expensive prescriptions. Reimbursement plays a critical role in how innovative treatments can enter the market. The cost of the medicine, compared to the benefit it provides to patients who are being treated, sometimes determines whether or not it will be reimbursed. Regulatory status, target population size, the setting of treatment, unmet needs, the number of incremental benefit claims, and prices can all affect market access and reimbursement possibilities.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Scope of the Report:

• The report covers a descriptive overview of Tregs, their mechanism of action, approvals timeline and background.
• Comprehensive insight has been provided into Tregs epidemiology.
• Additionally, an all-inclusive account of both the current and emerging Tregs is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
• A detailed review of the Tregs market; historical and forecasted is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Tregs market.

Tregs Report Insights

• Patient Population
• Therapeutic Approaches
• Tregs Pipeline Analysis
• Tregs Market Size and Trends
• Market Opportunities
• Impact of Upcoming Therapies

Tregs Report Key Strengths

• Eleven Years Forecast
• 7MM Coverage
• Tregs Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Tregs Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)

FAQs:

• What was the Tregs market share (%) distribution in 2020 and what it would look like in 2034?
• What would be the Tregs total market size as well as market size by therapies across the 7MM during the study period (2020-2034)?
• Which country will have the largest Tregs market size during the study period (2020-2034)?
• What are the burdens and unmet needs of Tregs?
• What is the Tregs targeted patient pool in the United States, EU4 (Germany, France, Italy, and Spain), and the UK, and Japan?
• What will be the growth opportunities across the 7MM concerning the patient population of Tregs?
• Which indication accounted for the highest number of indication-wise eligible cases in the United States, EU4 (Germany, France, Italy, and Spain), and the UK, and Japan?
• How many emerging therapies are in the mid-stage and late stage of development?
• Which inidication will be the major market share contributor in 2034 in the 7MM?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and licensing activities related to Tregs therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed?
• What are the clinical studies going on for Tregs and their status?
• What are the key designations that have been granted for the emerging therapies for Tregs?

Reasons to buy:

• The report will help in developing business strategies by understanding trends shaping and driving Tregs.
• To understand the future market competition in the Tregs market and Insightful review of the SWOT analysis of Tregs.
• Organize sales and marketing efforts by identifying the best opportunities for Tregs in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Key Events

5. Epidemiology and Market Forecast Methodology

6. Tregs Market Overview at a Glance by Indication in the 7MM

• 6.1. Market Share (%) Distribution by Indication in 2028
• 6.2. Market Share (%) Distribution by Indication in 2034

7. Tregs Market Overview at a Glance in the 7MM

• 7.1. Market Share (%) Distribution by Therapies in 2028
• 7.2. Market Share (%) Distribution by Therapies in 2034

8. Disease Background and Overview

• 8.1. Introduction
• 8.2. Tregs and its Classification
• 8.3. Potential of Tregs in the Treatment of Different Indications
• 8.4. Biomarkers Related to Tregs
• 8.5. Clinical Applications of Tregs

9. Epidemiology and Target Population

• 9.1. Key Findings
• 9.2. Assumptions and Rationale: 7MM
• 9.3. Epidemiology Scenario in the 7MM
  • 9.3.1. Total Cases of Selected Indications in the 7MM
  • 9.3.2. Indication-wise Eligible Cases in the 7MM
  • 9.3.3. Indication-wise Treated Cases in the 7MM

10. Emerging Drugs

• 10.1. Key Competitors
• 10.2. Orca-T: Orca Bio
  • 10.2.1. Product Description
  • 10.2.2. Other Development Activities
  • 10.2.3. Clinical Development
    • 10.2.3.1. Clinical Trial Information
  • 10.2.4. Safety and Efficacy
• 10.3. RAPA-501: Rapa Therapeutics
  • 10.3.1. Product Description
  • 10.3.2. Other Developmental Activities
  • 10.3.3. Clinical Development
    • 10.3.3.1. Clinical Trial Information
• 10.4. TRK-001: TRACT Therapeutics and Taiwan Bio Therapeutics
  • 10.4.1. Product Description
  • 10.4.2. Other Developmental Activities
  • 10.4.3. Clinical Development
    • 10.4.3.1. Clinical Trial Information
  • 10.4.4. Safety and Efficacy
• 10.5. ILT-101: ILTOO Pharma
  • 10.5.1. Product Description
  • 10.5.2. Other Developmental Activities
  • 10.5.3. Clinical Development
    • 10.5.3.1. Clinical Trial Information
  • 10.5.4. Safety and Efficacy
• 10.6. Rezpegaldesleukin (REZPEG, NKTR-358, LY3471851): Nektar
  • 10.6.1. Product Description
  • 10.6.2. Other Development Activities
  • 10.6.3. Clinical Development
    • 10.6.3.1. Clinical Trial Information
  • 10.6.4. Safety and Efficacy
• 10.7. PTG-007: PolTREG
  • 10.7.1. Product Description
  • 1.1.2. Other Development Activities
  • 10.7.2. Clinical Development
    • 10.7.2.1. Clinical Trial Information
  • 10.7.3. Safety and Efficacy
• 10.8. RGI-2001: REGiMMUNE
  • 10.8.1. Product Description
  • 10.8.2. Other Development Activities
  • 10.8.3. Clinical Development
    • 10.8.3.1. Clinical Trial Information
  • 10.8.4. Safety and Efficacy
• 10.9. QEL-001: Quell Therapeutics
  • 10.9.1. Product Description
  • 10.9.2. Other Developmental Activities
  • 10.9.3. Clinical Development
    • 10.9.3.1. Clinical Trial Information
  • 10.9.4. Safety and Efficacy
• 10.10. GIM-531: Georgiamune
  • 10.10.1. Product Description
  • 10.10.2. Other Developmental Activities
  • 10.10.3. Clinical Development
    • 10.10.3.1. Clinical Trial Information
• 10.11. TX200 (TX200-TR101): Sangamo Therapeutics
  • 10.11.1. Product Description
  • 10.11.2. Other Developmental Activities
  • 10.11.3. Clinical Development
    • 10.11.3.1. Clinical Trial Information
• 10.12. EGL-001: Egle Therapeutics
  • 10.12.1. Product Description
  • 10.12.2. Other Development Activities
  • 10.12.3. Clinical Development
    • 10.12.3.1. Clinical Trial Information
  • 10.12.4. Safety and Efficacy
• 10.13. Tivumecirnon (FLX475): RAPT Therapeutics
  • 10.13.1. Product Description
  • 10.13.2. Other Development Activities
  • 10.13.3. Clinical Development
    • 10.13.3.1. Clinical Trial Information
  • 10.13.4. Safety and Efficacy
• 10.14. TRX103: Tr1X
  • 10.14.1. Product Description
  • 10.14.2. Other Development Activities
  • 10.14.3. Clinical Development
    • 10.14.3.1. Clinical Trial Information
  • 10.14.4. Safety and Efficacy
• 10.15. IPG7236: Nanjing Immunophage Biotech
  • 10.15.1. Product Description
  • 10.15.2. Other Development Activities
  • 10.15.3. Clinical Development
    • 10.15.3.1. Clinical Trial Information
  • 10.15.4. Safety and Efficacy
• 10.16. CK0804: Cellenkos and Incyte
  • 10.16.1. Product Description
  • 10.16.2. Other Developmental Activities
  • 10.16.3. Clinical Development
    • 10.16.3.1. Clinical Trial Information
  • 10.16.4. Safety and Efficacy
• 10.17. ABA-101: Abata Therapeutics
  • 10.17.1. Product Description
  • 10.17.2. Other Developmental Activities
  • 10.17.3. Clinical Development
    • 10.17.3.1. Clinical Trial Information
• 10.18. NP001 Cell Injection: Novabio Therapeutics
  • 10.18.1. Product Description
  • 10.18.2. Clinical Development
    • 10.18.2.1. Clinical Trial Information
• 10.19. CK0801: Cellenkos
  • 10.19.1. Product Description
  • 10.19.2. Other Developmental Activities
  • 10.19.3. Clinical Development
    • 10.19.3.1. Clinical Trial Information
  • 10.19.4. Safety and Efficacy
• 10.20. SBT-77-7101: Sonoma Biotherapeutics
  • 10.20.1. Product Description
  • 10.20.2. Other Development Activities
  • 10.20.3. Clinical Development
    • 10.20.3.1. Clinical Trial Information
  • 10.20.4. Safety and Efficacy
• 10.21. CK0803: Cellenkos
  • 10.21.1. Product Description
  • 10.21.2. Other Development Activities
  • 10.21.3. Clinical Development
    • 10.21.3.1. Clinical Trial Information
• 10.22. SBT-11-5301: Sonoma Biotherapeutics
  • 10.22.1. Product Description
  • 10.22.2. Other Development Activities
  • 10.22.3. Clinical Development
    • 10.22.3.1. Clinical Trial Information
• 10.23. COYA 302: Coya Therapeutics and Dr. Reddy's Laboratories
  • 10.23.1. Product Description
  • 10.23.2. Other Developmental Activities
  • 10.23.3. Safety and Efficacy
• 10.24. CUG252: Cugene/AbbVie
  • 10.24.1. Product Description
  • 10.24.2. Other Development Activities
  • 10.24.3. Clinical Development
    • 10.24.3.1. Clinical Trial Information
• 10.25. DT2216: Dialectic Therapeutics
  • 10.25.1. Product Description
  • 10.25.2. Other Development Activities
  • 10.25.3. Clinical Development
    • 10.25.3.1. Clinical Trial Information

11. Tregs: 7MM analysis

• 11.1. Key Findings
• 11.1. Market Outlook
• 11.2. Conjoint Analysis
• 11.3. Key Market Forecast Assumptions
• 11.4. Market Size of Tregs in the 7MM
• 11.5. United States Market Size
  • 11.5.1. Market size of Tregs by Indications in the United States
  • 11.5.2. Market Size by Therapies in the United States
• 11.6. EU4 and the UK Market Size
  • 11.6.1. Market size of Tregs by Indications in EU4 and the UK
  • 11.6.2. Market Size by Therapies in EU4 and the UK
• 11.7. Japan Market Size
  • 11.7.1. Market size of Tregs by Indications in Japan
  • 11.7.2. Market Size by Therapies in Japan

12. Unmet Needs

13. SWOT Analysis

13. KOL Views

15. Market Access and Reimbursement

• 15.1. United States
  • 15.1.1. Centre for Medicare and Medicaid Services (CMS)
• 15.2. EU4 and the UK
  • 15.2.1. Germany
  • 15.2.2. France
  • 15.2.3. Italy
  • 15.2.4. Spain
  • 15.2.5. United Kingdom
• 15.3. Japan
  • 15.3.1. MHLW

16. Appendix

• 16.1. Bibliography
• 16.2. Report Methodology

17. DelveInsight Capabilities

18. Disclaimer

19. About DelveInsight